CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 4.3% – Time to Sell?

CNS Pharmaceuticals, Inc. ( NASDAQ:CNSP – Get Free Report )’s share price traded down 4.3% on Friday .

The stock traded as low as $0.11 and last traded at $0.12.



9,849,799 shares traded hands during mid-day trading, an increase of 73% from the average session volume of 5,706,537 shares. The stock had previously closed at $0.13.

Analyst Upgrades and Downgrades Separately, Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research note on Tuesday, September 10th. Check Out Our Latest Stock Report on CNSP CNS Pharmaceuticals Trading Down 4.

3 % Hedge Funds Weigh In On CNS Pharmaceuticals A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC boosted its position in CNS Pharmaceuticals, Inc. ( NASDAQ:CNSP – Free Report ) by 616.

6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 94,246 shares of the company’s stock after buying an additional 81,094 shares during the period. Virtu Financial LLC owned approximately 0.

80% of CNS Pharmaceuticals worth $34,000 as of its most recent SEC filing. 14.02% of the stock is currently owned by institutional investors and hedge funds.

CNS Pharmaceuticals Company Profile ( Get Free Report ) CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. Featured Articles Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.

com's FREE daily email newsletter ..